Abstract
Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Current HIV Research
Title: Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates.
Volume: 5 Issue: 2
Author(s): Radmila Metlas, Tanja Srdic and Veljko Veljkovic
Affiliation:
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Abstract: Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Export Options
About this article
Cite this article as:
Metlas Radmila, Srdic Tanja and Veljkovic Veljko, Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates., Current HIV Research 2007; 5 (2) . https://dx.doi.org/10.2174/157016207780077093
DOI https://dx.doi.org/10.2174/157016207780077093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Targeting Polymeric Nanobiomaterials as a Platform for Cartilage Tissue Engineering
Current Pharmaceutical Design Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews Metabolic Pathways of Ochratoxin A
Current Drug Metabolism Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Glaucoma: Validated and Facile In Vivo Experimental Models of a Chronic Neurodegenerative Disease for Drug Development
Current Medicinal Chemistry - Central Nervous System Agents Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Editorial [Hot-Topic: Optimizing a Therapeutic With Anti-Inflammatory Agents:Novel Drug Delivery Systems (Guest Editor: Carla Martins Lopes)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease
Current Neuropharmacology PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adenovirus and Post-Infectious Bronchiolitis Obliterans in Children
Current Pediatric Reviews Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile
Current Drug Safety Microglial Senescence
CNS & Neurological Disorders - Drug Targets Editorial: [Hot Topic HIV and Substance Abuse]
Current HIV Research Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences Editorial (Hot Topic: Neuroprotection Against Stroke and CNS Injury: New Mechanisms, Targets, and Controversies)
CNS & Neurological Disorders - Drug Targets